Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | METAP2 | P50579 | 3/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201452 | 0.86 | ACLY (0.74) | ACLYCA1CA2CA4CA7 | |
| SCHEMBL2499921 | 0.85 | LMNA (0.67) | CA1CA2CA4CA7CA9 | |
| SCHEMBL7409071 | 0.81 | LMNA (0.71) | ACLYMETAP2LMNAHTTMAPT | |
| SCHEMBL492089 | 0.81 | METAP2 (0.80) | ACLYMETAP2LMNAALDH1A1GAA | |
| SCHEMBL12201453 | 0.81 | KEAP1 (0.56) | ACLYMETAP2MCL1CYP2C9CYP2C19 | |
| SCHEMBL12201251 | 0.80 | LMNA (0.65) | METAP2CYP2C9LMNAHTTMAPT | |
| SCHEMBL12200971 | 0.79 | METAP2 (0.79) | METAP2MCL1CYP2C9LMNAALDH1A1 | |
| SCHEMBL7580401 | 0.79 | CA1 (0.70) | CA1CA2CA4CA7CA9 | |
| Lithium Ion SCHEMBL6112282 | 0.78 | METAP2 (0.64) | ACLYCA1CA2CA4CA7 | |
| SCHEMBL12201465 | 0.78 | CYP2C9 (0.60) | METAP2CYP2C9CYP2C19LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385820-B1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | KCNH1, KCNH2, KCNJ2 | ACLY 1447/4885CA1 1437/4885CA2 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.